Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company, revealed that its data will be featured at the 63rd Annual Symposium of ISCEV in Sydney, Australia from July 6-11, 2026, and at the ASRS 2026 Annual Meeting in Montréal, Canada from July 15-18, 2026. The company focuses on innovative therapeutics for degenerative retinal diseases with substantial unmet medical needs.